0
selected
-
1.
Treatment of Red Blood Cells with the INTERCEPT Blood System for pathogen inactivation for use in a double blinded phase III study preserves physiological erythrocyte morphology
Paranikulangara P, Brixner V, Dombos S, Weber I, Leibacher J, Heldke S, Graminske S, Ravanat C, Erickson A, North A, et al
Transfusion Medicine and Hemotherapy. 2016;43((Suppl. 1)):51.. p04-3 .
-
2.
Quality parameters of red blood cells treated with INTERCEPT pathogen inactivation system using S-303: A phase III clinical trial in cardiac surgery patients
Dombos S, Weber I, Brixner V, Pfeiffer H-U, Müller M, Geisen C, Leibacher J, Wotapek T, Janetzko K, Henschler R, et al
Transfusion Medicine and Hemotherapy. 2015;42((Suppl. 1)):5.. Abstract no. FV-02-3.
-
3.
Clinical safety and efficacy of red blood cell components treated with the second generation s-303 pathogen and leukocyte inactivation system – a randomized controlled double-blind phase 3 study in patients requiring transfusion support of acute anemia
Brixner V, Kiessling AH, Madlener K, Leibacher J, Muller M, Geisen C, Henschler R, North A, Huang N, Mufti N, et al
Transfusion Medicine and Hemotherapy. 2015;42((Suppl. 1)):4.. Abstract no. FV-02-1.